London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
@Keithbfk, apologies if I've made this point before, but Fortacin promotion was as for any minor speciality product, with responsibility devolved to national subsidiaries. The Italian, Spanish and Portuguese language websites were a decent enough blend of punter and HCP information, with Germany and France being HCP promotion only.
Pre and post-launch HCP promotion was conducted through conference presentations, paid for "expert" publication and prescriber panel surveys (Italy only). The lack of prescriber interest is down to the unremarkable nature of the product and the absence of differentiating clinical data. The expected return is too low to justify further clinical studies or, with the decline in the urology franchise, continued prescriber engagement. Move to OTC is just a last throw of the dice, in the hope that it might somehow rattle along with the other sub-€1m odds and sods in the consumer product bucket.
very interesting take bignose. technically the category of recipient is a bit wider (it can include service providers and the bod does i think have a bit of discretion as to recipients) but essentially your line of thinking is very intriguing..
My Mind is just a buzzin today. Speculating this, speculating that and even just speculating on the speculations...lol
Hopefully the delay is an indication of something more positive going on in the background and the TO may even be shelved, given the sudden announcement on options.
Remember it is only a "Directors and Employee share scheme". And there are still 37mill unaccounted for shares. The only logical person who is worth maybe half or all of them is Dr Mike ??? I'll let you speculate as to probably why...... :-)
All speculation, but the remaining shares have got to have been offered to someone somewhere in the company ?
morning all.so bignose your prediction of possible market indifference to the delay was correct.let us hope it is indicative of market focus on the prospects of fortacin as the real area of importance, which of course it is.
Either That or through a lack of promotion, they were hoping to obtain the license dirt cheap. Once obtained, they would then ramp up and even launch in many more countries (was it also a game plan to obtain the OTC approval after a couple of years bad sales ?) ........ A nice though, but I suspect there may be some clauses to prevent this ???
All speculation on my part, but of course these days, no one knows what devious plans companies have, one just has to look at RPG over the years with all their lies and misleading information as an example. ????
:-O
It is indeed a sad indictment that I am no longer surprised by the continuing delays and procrastination. I have always wondered why Recordati actually bothered to get on board with RP given that they have shown a significant lack of enthusiasm for promoting Fortacin. It always seemed that the product, in their eyes, was an afterthought. I seem to remember looking at their website and there was a disconnect between which countries they were supposedly promoting Fortacin and the reality of the situation. Perhaps it is all a cunning plan to keep everything under the radar!!
does anyone have any idea if any there is any significance to all these management share option announcements ?
well its what we are all still hoping for .always a good idea to remember how small our M/C is when viewed from the perspective of even modest potential.
All they have to do is get this sorted and get a license agreement which could theoretically unlock the US
(41.25m sufferers) which could lead to the Lat Am (81.25m sufferers) And the ME (51.375m sufferers)
Total (173.875m sufferers) even with a small % it could skyrocket the SP from zero to infinity and beyond.... LOL.
It certainly would give the SP a hell of a kick in the pants even before approval.
Certainly makes one wonder why they don't want to get this sorted asap instead of fannying about on other useless things. Or is all the fannying about just an attempt at an excuse to pay huge unjustified salaries ????